As COVID-19 cases continue to see a spike, there is some good news on the horizon.
Indian pharma major Serum Institute has initiated Phase 2 and 3 of clinical trials of its COVID-19 vaccine on 1600 healthy adults to evaluate its safety, efficacy and immune response. Pune-based Serum Institute has partnered with AstraZeneca for manufacturing coronavirus vaccine candidate developed by University of Oxford.
As per Clinical Trial Registry India, the scientific title of the study says that phase 2/3 clinical trial will be observer-blind, randomised, controlled study to determine the safety and immunogenicity of Covishield (COVID-19 vaccine) in healthy Indian adults.
Serum Institute got the approval from Drugs Controller General of India (DCGI) earlier this month for the trials. The vaccine is likely to be tested on adults spread across 17 cities in the country.
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram